Lieff Cabraser Heimann & Bernstein, LLP - Securities and Investment Fraud
   
 

Ancure Endograft Class Action and Lawsuits

Description of Ancure Endograft Device
On June 12, 2003, federal prosecutors charged Endovascular Technologies with 10 felony counts, including false statements to the Food and Drug Administration (FDA) in connection with the Ancure device.
The Ancure device is used to treat an abdominal aortic aneurysm, a weak spot in the wall of the large artery that carries blood from the heart to branch arteries throughout the body. The device consists of a delivery system and an implant. In a minimally invasive operation, a surgeon makes a small incision in the patient's groin, inserts a tube (catheter) through the artery, and implants a graft into the aorta in the abdomen. The graft stays in the body permanently, but the delivery catheter is removed.
Ancure Heart Device Defect Explained
The Ancure endograft device was made by EndoVascular Technologies (EVT) of Menlo Park, California, a subsidiary of Indianapolis-based Guidant Corporation.
Criminal Complaint Over the Ancure Device
Lieff Cabraser attorneys represent Ancure patients in personal injury lawsuits. Federal prosecutors alleged that the Ancure device often malfunctioned and Guidant asked doctors to use it in ways not approved by the government.
For example, when a surgeon could not remove part of a medical device stuck in a patient with a serious heart condition, Guidant's sales representative recommended breaking the product's handle -- a procedure that was not approved by the FDA.
EVT was charged with two counts of failing to report as many as 2,600 malfunctions of the device, thus preventing the public and physicians from learning about "recurring malfunctions and other risks."
 
Lieff Cabraser represents persons across America injured by defective Guidant and Ancure heart devices. Our firm was one of the first law firms in the U.S. to file a Guidant defibrillator recall lawsuit.
EVT was also accused of failing to report that other, more invasive operations were required after the device failed. The same day the complaint was filed, EVT plead guilty to the charges and eventually paid more than $92 million in fines.
Ancure Recall
EVT informed the FDA during a 19-month period from September 1999, when the FDA approved the device, until March 2001, when the company withdrew it from the market, of 172 malfunctions of the device and injuries to patients during surgery to insert it. In March 2001, EVT admitted that it had failed to submit an additional 2,628 incidents out of a total of 7,632 medical devices sold. Among the unreported incidents were 12 deaths and 57 emergency operations performed when the device's delivery system became stuck in the patient's body.
After withdrawing the Ancure device from the market in March 2001, Guidant and EVT reintroduced the device in August 2001 with FDA-approved modifications in the device's warnings to customers and instructions to doctors. On June 16, 2003, Guidant announced that it would stop making the Ancure Endograft System.
Legal Rights of the Injured
The law in most states provides individuals with legal claims and the right to compensation for injuries they suffer as a result of a defective product or the negligence of another. The injured person may file a lawsuit seeking compensation for his or her pain and suffering, medical expenses, lost past and future wages and punitive damages.
Damages sought against manufacturers of an allegedly defective medical device typically include damages for:
  • Physical pain and suffering, mental anguish and physical impairment;
  • Medical expenses associated with the allegedly defective product; and
  • Loss of earnings and/or earning capacity.
 
Our Guidant defect lawyers have years of experience successfully representing patients with faulty or defective medical implants.
There is no charge or obligation
for our review of your case.
We are pleased to visit Guidant patients, or families of loved ones who died, at or near where you live and at no cost, to discuss your legal rights and answer your questions.
To assist our clients with their claims, we have on staff nurses with cardiac training and have retained physicians to provide expert advice.
About Lieff Cabraser
Founded in 1972, Lieff Cabraser Heimann & Bernstein, LLP is a 50-plus attorney law firm with offices in San Francisco, New York and Nashville. For each of the last four years, the National Law Journal has recognized Lieff Cabraser as one of the top plaintiffs’ law firms in America.
For our personal injury cases, we bring a team of experienced lawyers. Each client is assigned an individual lawyer. In addition, we have on staff multiple nurses, legal assistants, scientific analysts and case clerks to assist the attorneys. To learn more about our firm, click here.
     Additional Lieff Cabraser Information: Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York and Nashville, is one of the largest law firms in the United States that only represents plaintiffs. We have been nationally recognized for our representation of shareholders in cases alleging violations of federal securities laws by major corporations and their directors and officers.
    Our clients come from across America, including the states of Alaska, Alabama, Arkansas, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, Montana, North Carolina, North Dakota, Nebraska, New Hampshire, New Jersey, New Mexico, Nevada, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Virginia, Vermont, Washington, Wisconsin, West Virginia and Wyoming. Learn more about our firm.
     Disclaimer: The hiring of legal professionals is an important decision that should not be based on advertising alone. Please read our disclaimer.
     Trademark Notice : The law firm of Lieff Cabraser Heimann & Bernstein, LLP, is in no way affiliated with Guidant Corporation or Endovascular Technologies, and any use of trademark information is for reference and informational purposes only.